Biotech Investing and Clinical Catalysts
Tracking public biotech market volatility, clinical trial readouts, and exit opportunities.
1 sourcesVoices in this topic
All paragraphs
Oct 23, 2026
- Brad Loncar Moderna’s cancer-vaccine selloff followed a valuation that “needed absolute perfection.” Sam Fazeli contrasts a market cap approaching $100 billion with roughly $2.2–2.3 billion in annual revenue and established melanoma …
- Matt Gline Unverified position-unwind theories may help explain biotech’s weak tape, but the panel cannot establish them as fact. Matt Gline describes shorts covering Moderna while selling longs, followed by benchmark-driven buying that compounded the divergence. Loncar …
- Biotech Hangout The panel sees a difficult quarter within a stronger financing and acquisition year. Chris Garabedian argues that the optimistic Endpoints survey largely captured conditions before the latest deterioration. Daphne Zohar says …
- Ali Mortazavi Silence’s announced 1.3 billion cash sale follows a long scientific and corporate reset. Ali Mortazavi recounts joining a £5 million AIM-listed company, abandoning an oncology program he distrusted, rebuilding around GalNAc …
- Biotech Hangout Tango’s pancreatic-cancer results provide the episode’s clearest example of strong clinical news meeting a falling share price. Eric Schmidt highlights an 82% response rate and 88% non-progression rate at nine months in heavily pretreated patients receiving its PRMT5 …
- Chris Garabedian China licensing remains active while proposed Treasury restrictions could disadvantage venture-backed company creation. Garabedian cites Roche’s 400 million upfront deal with 15 billion in headline “biobucks” and Gilead’s 1.3 billion upfront oral-peptide IL-23 …
Oct 16, 2026
- Biotech Hangout Index strength masks weakness in many underlying holdings and a historic de-grossing episode. XBI remained up 20% YTD but had fallen to roughly 146 from an August high of 169, while XLV accelerated from 7% to 15% YTD. Goldman …
- Brian Skorney The panel sees fund flows and psychology, not a sector-wide valuation bubble, as the immediate problem. Crowded longs are being sold while crowded shorts are covered, creating a self-reinforcing cycle in which nobody wants to “catch a falling …
- Biotech Hangout M&A remains the clearest potential reset, but rates and fund calendars may need to clear first. Matteis argued that acquisitions could provide the external validation and FOMO needed to restart buying; Werber pointed to many funds’ …
- Jake Becraft The IPO window remains open, but it increasingly rewards clinical catalysts and differentiated technology. TRex Bio raised $117 million, Iambic Therapeutics $150 million and City Therapeutics an upsized $200 million, bringing the unofficial 2026 …
- Biotech Hangout Bristol’s admilparant Phase III supports LPA1 in IPF, but its dose response left the class only partially de-risked. The low dose reached statistical significance while the high dose did not; the panel still saw a likely approval and potentially large …
- Yaron Werber Immunology produced both platform validation and a warning against extrapolating Phase II biology. Mirum’s Livmarli generated consistent pruritus reductions across additional pediatric cholestatic diseases, while three competing celiac …
Oct 12, 2026
Oct 2, 2026
- Biotech Hangout Biotech’s headline performance remains strong—XBI was up 27% through September versus 7% for XLV, 13% for the S&P 500, and 17% for Nasdaq—but the index masks a punishing ownership unwind. Eric Schmidt said underowned and heavily shorted stocks such as Moderna, Iovance, and Summit propped up Q3 while specialist-fund favorites …
- The Regeneron–Sanofi reunion is strategically logical but arrived with almost no surprise premium. Their four-program immunology extension gives Regeneron $1 billion upfront, up to $7 billion in milestones, and a 50/50 global P&L while …
- AstraZeneca’s $2 billion premium-priced Summit investment signals strategic interest in PD-1/VEGF while leaving HARMONi-3’s clinical risk fully intact. Eric said Summit told him AstraZeneca had not seen efficacy data unavailable to public investors, but the deal supplies badly needed …
- Three China-origin transactions reinforced China’s role in global pipeline sourcing. Novo paid $300 million upfront for Hengrui’s Phase I-ready GLP-1/GIP agonist HRS-1596; Merck committed $400 million upfront for preclinical …
- Clinical wins produced radically different stock outcomes depending on expectations and financing. Kodiak more than doubled on positive Phase III wet-AMD data, while Immix fell almost 10% despite an 89% complete-response rate in 45 …
- Brian Skorney The gene-therapy debate has shifted from whether a construct produces protein to whether delivery and expression create durable clinical benefit. Brian Skorney contrasted clear biological successes in tractable settings with Sarepta’s microdystrophin experience, where protein …
Sep 25, 2026
- Biotech Hangout The panel read September’s biotech pullback as nervous consolidation, not a broken sector thesis. XBI was down roughly 4% month to date and 9%-10% from its highs but still up about 30% for the year; higher rates, trial failures, scarce …
- Paul Matteis Xenon’s depression-study pause created a much larger franchise scare than the disclosed adverse events appeared to justify. Cognitive events including confusion, aphasia and a couple of reported psychosis cases prompted an enrollment pause, yet Paul Matteis …
- Biotech Hangout Reverse mergers have become a credible, well-funded alternative to biotech IPOs rather than a refuge for inferior companies. NorthX Immunology reverse-merged into Aethlon Medical and completed a PIPE. Eric Schmidt counted 21 IPOs and somewhat fewer than 20 reverse …
- Paul Matteis Sionna’s failed add-on study strengthened the presumption that Vertex’s cystic-fibrosis moat is technological, not merely commercial. Post-hoc explanations—including reduced Vertex-drug exposure—remain difficult to prove, so Matteis’s new null hypothesis is to “believe what …
- Rare disease appears to be entering a “phoenix rising from the ashes” phase, but the industry still has not solved one-time therapy economics. New approvals and encouraging cell- and gene-therapy programs follow years of efficacy, safety, manufacturing and regulatory setbacks; …
- Adam Feuerstein Regulatory flexibility remains inseparable from the obligation to prove that rare-disease drugs work. Ten years after eteplirsen’s accelerated approval, its confirmatory study was still unfinished; Adam Feuerstein supported requiring …
- Matt Gline Biotech’s headline tape remains healthy, but a rough week exposed heavy long-short degrossing and renewed sensitivity to rising rates. The XBI is only modestly below its recent peak, 22 IPOs are trading, and average IPO proceeds are the highest in the period Fazeli checked, …
- The MFN agreements look more constructive than feared because they seek higher overseas contributions rather than simply cutting U.S. prices. Pfizer’s partially redacted agreement apparently gives the government a share of incremental revenue if foreign prices rise; Gline called …
- Biotech Hangout Europe’s constrained budgets could turn MFN’s intended rebalancing into restricted access—or open the market to cheaper Chinese drugs. Sam Fazeli argued that energy, defense and weak growth leave little room for European drug-price increases; governments might instead limit …
- Heidi Overton’s confirmation hearing signaled a more industry-compatible FDA, although Compass Therapeutics showed that evidentiary standards remain demanding. Overton emphasized faster innovation, competition with China and stated that MMR—and every vaccine on the U.S. market, according to the …
- The week’s renal and autoimmune data expanded credible markets while preserving sharp competitive questions. Vertex’s inaxaplin supported APOL1 efficacy beyond FSGS in non-diabetics, but diabetes still looks difficult and Maze re-entered the …
- Viking and Celldex produced commercially meaningful profiles in markets where durability and safety matter as much as headline efficacy. VK2735 delivered 19% placebo-adjusted weight loss at 21 weeks, retaining 97% with every-other-week maintenance and 90% with monthly dosing; …